Get the Stockscreener App
1.74
4.50%
0.075
Pre-market:
1.70
-0.04
-2.30%
Inmune Bio Inc stock is traded at $1.74, with a volume of 1.79M.
It is up +4.50% in the last 24 hours and up +38.10% over the past month.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
See More
Previous Close:
$1.665
Open:
$1.67
24h Volume:
1.79M
Relative Volume:
2.78
Market Cap:
$46.26M
Revenue:
$50,000
Net Income/Loss:
$-41.60M
P/E Ratio:
-1.0268
EPS:
-1.6946
Net Cash Flow:
$-20.20M
1W Performance:
+6.75%
1M Performance:
+38.10%
6M Performance:
+10.13%
1Y Performance:
-24.35%
1-Day Range:
$1.54
$1.85
1-Week Range:
$1.54
$1.85
52-Week Range:
$1.09
$3.244
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.74 | 46.26M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Form 4 INmune Bio Inc For: 7 July By Investing.com - Investing.com South Africa
Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40 - Stock Titan
INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan
Inmune Bio (INMB) CEO exercises 9,014 April 2024 warrants at $1.40 - Stock Titan
Price to book forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Inmune Bio Inc outlines its immunotherapy focus as shares trade on Nasdaq - AD HOC NEWS
Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference - 富途牛牛
Is INmune Bio (NASDAQ:INMB) In A Good Position To Invest In Growth? - Sahm
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
INmune Bio Executes Warrant Inducement and Extension Agreement - TipRanks
INMB Seeks Patent Approval for CORDStrom Platform - GuruFocus
INmune Bio files U.S. patent for cell therapy platform - Investing.com
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
INmune Bio files U.S. patent for cell therapy platform By Investing.com - Investing.com Canada
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion - The Manila Times
INmune Bio moves CORDStrom into U.S. patent review - Stock Titan
Price to sales forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Price to earnings forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM:INMB) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Dynamic Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio, Inc. Actuals & Estimates (NASDAQ:INMB) - TradingView
Inmune Bio total assets 2021-2025 - Statista
INmune Bio receives UK regulatory approval for RDEB treatment plan By Investing.com - Investing.com Australia
INMB Forecast — Price Target — Prediction for 2027 - TradingView
INMB Secures UK Regulatory Approval for Pediatric Treatment Plan - GuruFocus
INmune Bio receives UK regulatory approval for RDEB treatment plan - Investing.com
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ - The Manila Times
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8 - Moomoo
INmune Bio Advances Ebstrocel Toward UK Conditional Approval - TipRanks
MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan
INMB Receives Regulatory Guidance for CORDStrom in Epidermolysis Bullosa - GuruFocus
INmune Bio receives MHRA alignment for RDEB therapy filing - Investing.com
INmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application - marketscreener.com
INmune Bio receives MHRA alignment for RDEB therapy filing By Investing.com - Investing.com India
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB - The Manila Times
INmune Bio wins MHRA backing for 2026 UK rare-disease filing - Stock Titan
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):